靶向CD14抑制巨噬细胞衰老并调控微环境以增强腱骨愈合
本研究在小鼠前交叉韧带重建(ACLR)模型中探讨巨噬细胞衰老在腱骨界面微环境中的作用,并评估靶向CD14能否减轻衰老从而增强腱骨愈合。结果显示,腱骨界面凋亡细胞触发的早期炎症反应导致巨噬细胞衰老、炎症通路激活、促炎因子分泌增加及CD14表达升高;靶向CD14可减少巨噬细胞衰老和炎症反应,从而促进腱骨愈合。作者认为CD14靶向治疗可能抑制巨噬细胞衰老、加速腱骨愈合,具有临床转化潜力。
要点
- 小鼠ACLR模型中,腱骨界面凋亡细胞触发的早期炎症反应导致巨噬细胞衰老和CD14表达升高。
- 靶向CD14可减少腱骨界面巨噬细胞衰老和炎症反应,从而增强腱骨愈合。
- 作者认为CD14靶向治疗可能抑制巨噬细胞衰老、加速腱骨愈合,具有临床转化潜力。
核心结论
- 腱骨界面微环境中的过度炎症促进巨噬细胞衰老,从而损害腱骨愈合。
- 靶向CD14可有效预防巨噬细胞衰老,促进腱骨愈合改善。
研究设计与样本
- 控制性实验室研究,采用小鼠ACLR模型评估腱骨愈合。
- 术后8周通过组织学染色、微计算机断层扫描分析骨隧道内新骨形成及移植物生物力学测试评估愈合。
- 采用β-半乳糖苷酶染色评估细胞衰老,免疫荧光和免疫组织化学分析蛋白表达水平。
- 通过t分布随机邻域嵌入投影评估腱骨界面巨噬细胞异质性,并使用CellChat、KEGG和GO分析研究衰老巨噬细胞特征。
- 采用碱性磷酸酶和茜素红S染色评估骨髓间充质干细胞的成骨分化。
主要发现
- 腱骨界面凋亡细胞触发的早期炎症反应导致巨噬细胞衰老、炎症通路激活、促炎因子分泌增加及CD14表达升高。
- 靶向CD14减少了腱骨界面巨噬细胞衰老和炎症反应,从而增加腱骨愈合。
临床怎么用
- 目前临床实践中缺乏增强ACLR术后腱骨愈合的靶向治疗药物。
- 作者认为CD14靶向治疗可能抑制巨噬细胞衰老、加速腱骨愈合,并具有显著的临床转化潜力。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: To date, no targeted pharmacological agents have been clinically available specifically for postoperative management after anterior cruciate ligament reconstruction (ACLR). PURPOSE: To elucidate the role of macrophage senescence in the tendon-bone interface microenvironment and assess whether targeting CD14 can mitigate senescence, thereby enhancing tendon-bone healing. STUDY DESIGN: Controlled laboratory study. METHODS: A murine ACLR model was used to evaluate the tendon-bone healing. Healing was assessed 8 weeks postsurgery through histological staining, micro-computed tomography analysis of neoplastic bone formation within bone tunnels, and biomechanical testing of tendon grafts. Cellular senescence was evaluated using β-galactosidase staining, while immunofluorescence and immunohistochemistry were used to analyze protein expression levels. Macrophage heterogeneity at the tendon-bone interface was assessed via t-distributed stochastic neighbor embedding projection, and senescent macrophage characteristics were investigated using CellChat, KEGG, and GO analyses. Alkaline phosphatase and Alizarin Red S staining were used to evaluate osteogenic differentiation of bone marrow mesenchymal stem cells. RESULTS: Early inflammatory responses triggered by apoptotic cells at the tendon-bone interface resulted in macrophage senescence, activation of inflammatory pathways, increased secretion of pro-inflammatory factors, and elevated CD14 expression. Targeting CD14 reduced macrophage senescence and the inflammatory response at the tendon-bone interface, thereby increasing tendon-bone healing. CONCLUSION: The findings indicate that excessive inflammation within the tendon-bone interface microenvironment promotes macrophage senescence, thereby impairing tendon-bone healing. Targeting CD14 effectively prevents macrophage senescence, facilitating improved tendon-bone healing. CLINICAL RELEVANCE: Currently, targeted therapeutics to enhance tendon-bone healing post-ACLR are lacking in clinical practice. The findings demonstrate that microenvironmental inflammation leading to macrophage senescence is a critical factor contributing to impaired tendon-bone healing. CD14-targeted therapy may inhibit macrophage senescence, accelerate tendon-bone healing, and offer significant translational potential for clinical application.
引用
- Yao J, Wu Y, Xu L, et al. Targeting CD14 to Inhibit Macrophage Senescence and Regulate the Microenvironment for Enhanced Tendon-Bone Healing. Am J Sports Med. 2025. PMID: 41108053. doi:10.1177/03635465251383161
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。